MktsMarkets

Metagenomi Therapeutics, Inc.
NASDAQ: MGXKey statistics
MGX News
Stories mentioning MGX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1,248 | 3,911 | 8,659 | 8,513 | 4,127 | 9,614 | 11,514 | 20,008 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 19,300 | 21,501 | 25,283 | 22,507 | 25,142 | 23,164 | 26,256 | 28,320 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 25,835 | 28,278 | 31,498 | 29,500 | 31,947 | 30,237 | 33,897 | 36,871 |
| Operating Income (Loss) | (24,587) | (24,367) | (22,839) | (20,987) | (27,820) | (20,623) | (22,383) | (16,863) |
| Interest Income | 1,539 | 1,884 | 2,214 | 2,485 | 2,887 | 3,196 | 3,616 | 3,976 |
| Interest Expense | ||||||||
| Other Expense | (1.00) | (11.00) | (2.00) | (70.00) | (8.00) | (49.00) | (57.00) | (51.00) |
| Pretax Income | (23,049) | (22,494) | (20,627) | (19,864) | (24,941) | (24,606) | (20,879) | (12,938) |
| Tax Provision | 10.00 | 34.00 | (234.00) | 44.00 | 98.00 | (1,208) | (2,106) | (2,199) |
| Net Income (Loss) | (23,059) | (22,528) | (20,393) | (19,908) | (25,039) | (23,398) | (18,773) | (10,739) |
| Earnings Per Share (Basic) | (0.61) | (0.60) | (0.55) | (0.54) | (0.68) | (0.71) | (0.51) | (0.29) |
| Earnings Per Share (Diluted) | (0.61) | (0.60) | (0.55) | (0.54) | (0.68) | (0.71) | (0.51) | (0.29) |
| Weighted Average Shares Outstanding (Basic) | 37,581 | 37,251 | 37,349 | 37,157 | 37,019 | 33,028 | 36,766 | 36,625 |
| Weighted Average Shares Outstanding (Diluted) | 37,581 | 37,251 | 37,349 | 37,157 | 37,019 | 33,028 | 36,766 | 36,625 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About MGX
Metagenomi Therapeutics, Inc. (NASDAQ: MGX) is a stock listed on the Nasdaq Stock Market under the ticker symbol MGX. It last traded at $0.6300 (Nov 18, 2026, 9:30 AM ET), up 0.1% on the day. That gives Metagenomi Therapeutics a market capitalisation of $26.8M.
Over the past 52 weeks MGX has traded between $0.6000 and $1.87.
Revenue for the quarter ended Mar 31, 2026 was $1.2M; a net loss of $23.1M. Revenue was down 69.8% from $4.1M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $1.2M | -$23.1M | -1847.7% |
| Dec 31, 2025 | $3.9M | -$22.5M | -576.0% |
| Sep 30, 2025 | $8.7M | -$20.4M | -235.5% |
| Jun 30, 2025 | $8.5M | -$19.9M | -233.9% |
From Metagenomi Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…